Class summary at a glance.

Every drug in the ACE Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $482.0Mcombined across class
Total Rx claims: 60.4M18.5M unique beneficiaries
Generic mfrs (active): 42across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Lisinopril

Brand: Qbrelis · 54.0M Part D claims (CY24) · 16.6M beneficiaries · First FDA approval: 2002-07-01

11 generic mfrs 0 plans require PA

Low NADAC$0.014

→

Avg plan cost$0.119

Part D spend $387.2M 8× spread, current vs floor

Class share

80%

of class CY24 spend

View profile →

Enalapril

Brand: Epaned · 2.9M Part D claims (CY24) · 873K beneficiaries · First FDA approval: 1985-12-24

12 generic mfrs 0 plans require PA

Low NADAC$0.063

→

Avg plan cost$0.223

Part D spend $56.0M 4× spread, current vs floor

Class share

12%

of class CY24 spend

View profile →

Benazepril

Brand: Lotensin · 3.2M Part D claims (CY24) · 991K beneficiaries · First FDA approval: 1991-06-21

10 generic mfrs 0 plans require PA

Low NADAC$0.046

→

Avg plan cost$0.073

Part D spend $32.8M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Fosinopril

297K Part D claims (CY24) · 91K beneficiaries · First FDA approval: 2004-04-23

5 generic mfrs 0 plans require PA

Low NADAC$0.164

→

Avg plan cost$0.182

Part D spend $5.8M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Quinapril

Brand: Quinapril · 2K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2005-03-02

4 generic mfrs 0 plans require PA Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend $193713

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.